Il ruolo nefroprotettivo del finerenone nei pazienti con diabete mellito tipo 1 - Renologia on air

🔥 T1D + CKD: A breakthrough has finally arrived! For the first time in 30 years, a therapy shows a concrete renoprotective effect in patients with type 1 diabetes. The FINE-ONE trial demonstrates that finerenone reduces albuminuria by 37%, with safety comparable to placebo. A possible paradigm shift for a high-risk population that has been overlooked by trials. Find out what really changes 👉🔍